![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/PANACEABIO.png)
Share the post "Panacea Biotec ‘s Q3 2024-25 Latest News: Profit Rises by 2144.19% YoY"
Highlights
🔹 The presented financial data is Standalone to provide a comprehensive overview of the company performance. 🔹 Sales over the Year and quarter: The company experienced a substantial growth of 13.86 % in the past year, substantial increase in net sales/revenue by 41.48 %. 🔹 Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 8.85 %. Marginal decrease of -2.64% in other income during this quarter. 🔹 Profit over the Year and quarter: Significant improvement in profitability for Panacea Biotec Limited. Notable increase of 2144.19 % in net profit Year to Year, Panacea Biotec Limited’s profitability increased by 648.06 % in this quarter. 🔹 EPS over the Year and quarter: EPS increased by 2,157.14 % Year to Year. EPS increased by 652.38 % in previous quarter. Positive impact on shareholders.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 95.23 Cr | Rs. 76.64 Cr | Rs. 108.43 Cr | + 41.48 % | + 13.86 % |
| Expenses | Rs. 88.59 Cr | Rs. 69.9 Cr | Rs. 93.04 Cr | + 33.1 % | + 5.02 % |
| Operating Profit | Rs. 6.64 Cr | Rs. 6.74 Cr | Rs. 15.39 Cr | + 128.34 % | + 131.78 % |
| OPM % | 6.97 % | 8.79 % | 14.19 % | + 5.4 % | + 7.22 % |
| Other Income | Rs. 3.05 Cr | Rs. 3.41 Cr | Rs. 3.32 Cr | -2.64 % | + 8.85 % |
| Interest | Rs. 3.41 Cr | Rs. 3.76 Cr | Rs. 3.85 Cr | + 2.39 % | + 12.9 % |
| Depreciation | Rs. 5.21 Cr | Rs. 5.09 Cr | Rs. 5.21 Cr | + 2.36 % | + 0 % |
| Profit before tax | Rs. 1.07 Cr | Rs. 1.3 Cr | Rs. 9.65 Cr | + 642.31 % | + 801.87 % |
| Tax % | 59.81 % | 0.77 % | 0 % | -0.77 % | -59.81 % |
| Net Profit | Rs. 0.43 Cr | Rs. 1.29 Cr | Rs. 9.65 Cr | + 648.06 % | + 2144.19 % |
| EPS in Rs | Rs. 0.07 | Rs. 0.21 | Rs. 1.58 | + 652.38 % | + 2157.14 % |
Today, we’re looking at Panacea Biotec Limited’s financial performance for the Q3(Dec 2024-25).Starting with the top line, the company reported a robust year-over-year sales growth of 13.86 %. However, it did see a marginal increase of 41.48 % from the previous quarter. Expenses ticked up slightly by 33.1 % quarter-on-quarter, aligning with the annual rise of 5.02 %. Operating profit, while up 131.78 % compared to last year, faced a quarter-on-quarter increase of 128.34 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 7.22 %, but an expansion of 5.4 % sequentially. Other income fell by -2.64 % compared to the last quarter, despite an annual growth of 8.85 %. Interest expenses surged remarkably by 2.39 % from the previous quarter, yet the year-over-year increase remains at a moderate 12.9 %. Depreciation costs climbed by 2.36 % quarter-on-quarter, whereas on an annual scale, they saw an increase of 0 %. Profit before tax grew annually by 801.87 % but saw an increase from the preceding quarter by 642.31 %.
Tax expenses as a percentage of profits decreased slightly by -59.81 % compared to last year, with a more notable quarter-on-quarter decrease of -0.77 %. Net profit rose by 2144.19 % year-on-year but experienced a 648.06 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual uptick of 2157.14 % but a quarterly rise of 652.38 %. In summary, Panacea Biotec Limited’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 95.23 Cr | Rs. 76.64 Cr | Rs. 108.43 Cr | + 41.48 % | + 13.86 % |
| Expenses | Rs. 88.59 Cr | Rs. 69.9 Cr | Rs. 93.04 Cr | + 33.1 % | + 5.02 % |
| Operating Profit | Rs. 6.64 Cr | Rs. 6.74 Cr | Rs. 15.39 Cr | + 128.34 % | + 131.78 % |
| Net Profit | Rs. 0.43 Cr | Rs. 1.29 Cr | Rs. 9.65 Cr | + 648.06 % | + 2144.19 % |
| EPS in Rs | Rs. 0.07 | Rs. 0.21 | Rs. 1.58 | + 652.38 % | + 2157.14 % |
In reviewing Panacea Biotec Limited’s 2024-25(Q3) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales saw a robust 13.86 % year-on-year growth, however, there was a minor increase of 41.48 % from the previous quarter. Expenses rose by 5.02 % compared to the previous year, with a 33.1 % increase quarter-on-quarter. Operating Profit surged by 131.78 % annually, and saw a 128.34 % increase from the last quarter.
Net Profit showed yearly increase of 2144.19 %, and experienced a 648.06 % increase from the previous quarter. Earnings Per Share (EPS) rose by 2157.14 % annually, however rose by 652.38 % compared to the last quarter. In essence, while Panacea Biotec Limited exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/shareholding/business-background-9sb4kpcblwpnrkzr.jpg)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/YOGISUNG.png)
![[fetch_key]](https://stocktradeupdates.com/wp-content/uploads/new_logos/KIRIINDUS.png)